Two of the leading experts on anti-obesity drugs say the drugs are heralding a new era in medicine and could soon be used to treat a raft of other conditions.

David Ricks, the chair and chief executive of Eli Lilly, and Dr. Fatima Cody Stanford, obesity medicine physician at Massachusetts General Hospital/Harvard Medical School, talk through the groundbreaking role of GLP-1 medications in transforming the treatment of obesity, and how the drug could potentially be used to treat alcohol use disorder or other addictions.

This interview was with Andrew Ross Sorkin of The New York Times at the annual DealBook Summit and recorded live in front of an audience at Jazz at Lincoln Center. Read more about highlights from the day at https://www.nytimes.com/live/2024/12/04/business/dealbook-summit-news

Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify.